Analysts Set Definitive Healthcare Corp. (NASDAQ:DH) Target Price at $5.35

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have received an average rating of “Hold” from the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $5.35.

Several research firms recently weighed in on DH. Stephens began coverage on Definitive Healthcare in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.00 price objective for the company. The Goldman Sachs Group reduced their price target on shares of Definitive Healthcare from $4.50 to $3.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Barclays dropped their price objective on shares of Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating on the stock in a research note on Monday, March 3rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a research note on Thursday, January 16th.

Definitive Healthcare Stock Performance

Shares of NASDAQ:DH opened at $2.59 on Tuesday. The firm’s 50 day simple moving average is $3.57 and its 200-day simple moving average is $4.10. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49. Definitive Healthcare has a one year low of $2.15 and a one year high of $7.66. The firm has a market cap of $292.44 million, a PE ratio of -0.84, a price-to-earnings-growth ratio of 4.06 and a beta of 1.48.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.04). The firm had revenue of $62.29 million for the quarter, compared to analysts’ expectations of $60.60 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. As a group, equities analysts predict that Definitive Healthcare will post 0.16 EPS for the current year.

Institutional Trading of Definitive Healthcare

A number of institutional investors have recently made changes to their positions in DH. Intech Investment Management LLC purchased a new position in shares of Definitive Healthcare in the 3rd quarter valued at approximately $55,000. Charles Schwab Investment Management Inc. increased its stake in Definitive Healthcare by 5.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 436,132 shares of the company’s stock valued at $1,950,000 after purchasing an additional 23,706 shares in the last quarter. Walleye Capital LLC raised its holdings in shares of Definitive Healthcare by 43.1% in the third quarter. Walleye Capital LLC now owns 44,507 shares of the company’s stock worth $199,000 after buying an additional 13,412 shares during the last quarter. Centiva Capital LP acquired a new stake in shares of Definitive Healthcare during the third quarter worth $185,000. Finally, Point72 DIFC Ltd lifted its stake in shares of Definitive Healthcare by 759.9% during the third quarter. Point72 DIFC Ltd now owns 9,296 shares of the company’s stock worth $42,000 after buying an additional 8,215 shares during the period. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.